When it comes to donating kidneys, women more giving to partners than men: Study

Agencies

March 8, 2018

Women are statistically far more likely to donate a kidney to a partner than receive one, according to a study released Thursday to coincide with World Kidney Day and International Women’s Day.

Based on European data assessed, 36 percent of women donate a kidney to their husband in clinically suitable cases.

That compares with just seven percent of clinically suitable men donating a kidney to their spouse, said the study by the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations.

It highlights how women are also liable to suffer from the most serious stages of chronic kidney disease (CKD) as they tend to live longer than male sufferers and take longer to reach a stage requiring a transplant.

"Although it is hard to pinpoint a specific reason for higher numbers of wives being donors than husbands, the evidence suggests women are motivated by reasons such as altruism and the desire to help their family continue to survive," said Adeera Levin, a Professor of Medicine at Canada's University of British Colombia.

The study data shows some two thirds of kidney transplant recipients are men although the gender difference was less pronounced for donations by deceased men and women.

Worldwide, the study found 14 percent of women suffer from CKD compared with 12 percent of men.

Although the data showed higher proportions of women live with advanced CKD, "experts believe that systemic failures to detect or manage CKD in women leave women at a higher risk of progression and complications."

This year's World Kidney Day is closely focusing on CKD sufferers who are either pregnant or wishing to conceive.

"In women who have had a successful kidney transplant, fertility can be at least partly restored and chances of successful birth increase," said Dr Giorgina Piccoli of Italy's University of Torino and the Centre Hospitalier Le Mans, France.

"However, complications in these women remain more common than in the general population, and preconception medical counselling should always be sought," added Piccoli.

She stressed the "clear need for higher awareness of CKD in pregnancy, to timely identify CKD in pregnancy, and to follow-up women with CKD during and after pregnancy."

Dr Piccoli also indicated pregnancy-related complications can increase the risk of kidney disease.

"Women face unique issues in relation to kidney disease and donation, and since this year’s World Kidney Day coincides with International Women’s Day, we decided now was the time to highlight these issues," said Professor Levin.

Comments

Add new comment

Coastaldigest.com reserves the right to delete or block any comments.
Coastaldigset.com is not responsible for its readers’ comments.
Comments that are abusive, incendiary or irrelevant are strictly prohibited.
Please use a genuine email ID and provide your name to avoid reject.

Remdesivir slows COVID-19 progression in macaques: Study

Agencies

June 10,2020

Early treatment with the antiviral drug remdesivir has been found to reduce viral load and prevent lung disease in macaques infected with SARS-CoV-2 that causes COVID-19, according to a study.

The findings, published in the journal Nature on Tuesday, support the early use of remdesivir treatment in patients with COVID-19 to prevent progression to pneumonia.

Researchers from the National Institutes of Health in the US noted that remdesivir has broad antiviral activity and has been shown to be effective against infections with SARS-CoV and MERS-CoV in animal models.

The drug is being tested in human clinical trials for the treatment of COVID-19, they said.

Researcher Emmie de Wit and colleagues investigated the effects of remdesivir treatment in rhesus macaques, a recently established model of SARS-CoV-2 infection.

Two sets of six macaques were inoculated with SARS-CoV-2.

One group was treated with remdesivir 12 hours later -- close to the peak of virus reproduction in the lungs -- and these macaques received treatment every 24 hours until six days after inoculation.

In contrast to the control group, the researchers found that macaques that received remdesivir did not show signs of respiratory disease, and had reduced damage to the lungs.

Viral loads in the lower respiratory tract were also reduced in the treated animals; viral levels were around 100 times lower in the lower-respiratory tract of remdesivir-treated macaques 12 hours after the first dose, they said.

The researchers said that infectious virus could no longer be detected in the treatment group three days after initial infection, but was still detectable in four out of six control animals.

Despite this virus reduction in the lower respiratory tract, no reduction in virus shedding was observed, which indicates that clinical improvement may not equate to a lack of infectiousness, they said.

Dosing of remdesivir in the rhesus macaques is equivalent to that used in humans, the researchers noted.

They cautioned that it is difficult to directly translate the timing of treatment used in corresponding disease stages in humans, because rhesus macaques normally develop only mild disease.

However, researchers said the results indicate that remdesivir treatment of COVID-19 should be initiated as early as possible to achieve the maximum treatment effect.

Comments

Add new comment

Coastaldigest.com reserves the right to delete or block any comments.
Coastaldigset.com is not responsible for its readers’ comments.
Comments that are abusive, incendiary or irrelevant are strictly prohibited.
Please use a genuine email ID and provide your name to avoid reject.

WHO suspends HCQ clinical trial on COVID-19 patients

Agencies

May 26,2020

Tedros Adhanom Ghebreyesus, the World Health Organisation's (WHO) Director-General, said that a clinical trial of hydroxychloroquine (HCQ) on COVID-19 patients has come to "a temporary pause", while the safety data of the the anti-malaria drug was being reviewed.

According to the WHO chief, The Lancet medical journal on May 22 had published an observational study on HCQ and chloroquine and its effects on COVID-19 patients that have been hospitalized, reports Xinhua news agency.

The authors of the study reported that among patients receiving the drug, when used alone or with a macrolide, they estimated a higher mortality rate.

"The Executive Group of the Solidarity Trial, representing 10 of the participating countries, met on Saturday (May 23) and has agreed to review a comprehensive analysis and critical appraisal of all evidence available globally," Tedros said in a virtual press conference on Monday.

The review will consider data collected so far in the Solidarity Trial and in particular robust randomized available data, to adequately evaluate the potential benefits and harms from this drug, he said.

"The Executive Group has implemented a temporary pause of the HCQ arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board. The other arms of the trial are continuing," Tedros added.

WHO initiated the Solidarity Trial, a plan to evaluate the safety and efficacy of four drugs and drug combinations against COVID-19 more than two months ago, which include HCQ.

According to the WHO, over 400 hospitals in 35 countries are actively recruiting patients and nearly 3,500 patients have been enrolled from 17 countries under the Solidarity Trial.

Tedros added that the safety concern over the drug related only to the use of HCQ and chloroquine in COVID-19, and "these drugs are accepted as generally safe for use in patients with autoimmune diseases or malaria".

"WHO will provide further updates as we know more," he added.

Comments